Biogen

This study is testing an investigational drug called litifilimab to see if it can better control disease activity in adults with active systemic lupus erythematosus (SLE). Participants, who are already taking standard lupus medications, receive either litifilimab or a placebo inj…

This study aims to learn about the long-term safety and effectiveness of a drug called litifilimab for adults with active systemic lupus erythematosus (SLE). It is an extension study for about 864 people who completed a previous 1-year trial, and will follow them for up to 3.5 ye…

This study aims to understand the long-term safety of several medications used to control multiple sclerosis (MS). Researchers will analyze health records from over 10,500 people with MS who are taking drugs like Vumerity or Tecfidera. The main goal is to track and compare the ra…

This study is testing a medication called BIIB017 for teenagers (ages 10-17) with relapsing-remitting multiple sclerosis (MS). The main goals are to see if the drug is safe, well-tolerated, and effective at reducing MS relapses and brain lesions over two years. It also includes a…

This study is testing whether an experimental drug called BIIB122 can slow down the worsening of Parkinson's disease symptoms. Researchers are enrolling 650 adults with early-stage Parkinson's (diagnosed within 2 years) to take either the drug or a placebo pill daily for 1 to 3 y…

This study aims to learn about the long-term safety and effectiveness of an investigational drug called litifilimab for adults with cutaneous lupus, a condition causing skin rashes and lesions. It will follow about 322 participants who previously benefited from the drug in an ear…

This study is testing an investigational drug called litifilimab for adults with active systemic lupus erythematosus (SLE). The goal is to see if adding monthly injections of litifilimab to a patient's standard lupus medications can better control the disease, reduce symptom flar…

This study follows 115 people with spinal muscular atrophy (SMA) for nearly six years to learn about the long-term safety of a higher dose of the drug nusinersen. Participants, who previously took part in a related study, receive the drug via a spinal injection every four months.…

This study is testing whether a drug called tofersen can delay or prevent the onset of ALS in adults who carry a specific genetic mutation (SOD1) and show early biological signs of the disease but do not yet have any symptoms. The trial will compare the drug to a placebo in about…

This study is creating a national registry to understand how spinal muscular atrophy (SMA) naturally progresses in children under 18 in China. It will also track how and when children receive approved SMA treatments in real-world settings. The goal is to gather knowledge to help …

This study aims to understand how often patients with relapsing-remitting multiple sclerosis (RRMS) develop antibodies against their treatment, natalizumab, when they switch from receiving it through an IV to a subcutaneous injection. It will observe about 400 patients in Europe,…